Portal de Periódicos da CAPES

Chlamydia, Smoking, and Heart Disease

1992; American College of Physicians; Volume: 117; Issue: 2 Linguagem: Inglês

10.7326/0003-4819-117-2-171_1

1539-3704

David L. Hahn,

Urinary Tract Infections Management

Letters15 July 1992Chlamydia, Smoking, and Heart DiseaseDavid L. Hahn, MDDavid L. Hahn, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-2-171_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Saikku and colleagues (1) present evidence of an association between chronic Chlamydia pneumoniae infection and the development of coronary heart disease in the Helsinki Heart Study. This association, if confirmed, could have a profound effect on the prevention and management of coronary heart disease. The odds ratios associating evidence of C. pneumoniae infection and coronary heart disease were attenuated (from 2.7 to 2.3 for immunoglobulin A [IgA] titers, 2.1 to 1.8 for immune complexes, and 2.9 to 2.6 for the presence of both factors). There was no statistical difference for IgA titers and immune complexes after controlling...Reference1. SaikkuLeinonenTenkanenLinnanmäkiEkmanManninen PMLEMV. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273-8. LinkGoogle Scholar1. HoltKeast PD. Environmentally induced changes in immunological function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. Bacteriol Rev. 1977;41:205-16. CrossrefMedlineGoogle Scholar2. SaikkuLeinonenTenkanenLinnenmäkiEkmanManninen PMLEMV. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273-8. LinkGoogle Scholar3. SaikkuLeinonenMattilaEkmanNieminenMäkelä PMKMMP. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-5. CrossrefMedlineGoogle Scholar4. LeinonenLinnanmäkiMattilaNieminenValtonenLeirisalo-Repo MEKMVM. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog. 1990;9:67-73. CrossrefMedlineGoogle Scholar5. FrickEloHaapaHeinonenHeinsalmiHelo MOKOPP. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntibiotika zur ReokklusionsprophylaxeChlamydia Pneumoniae and Coronary Heart Disease 15 July 1992Volume 117, Issue 2Page: 171-171KeywordsCOVID-19Cardiovascular therapyChlamydiaChlamydia infectionCoronary heart diseaseImmune complexInfectious disease immunologyInfectious diseasesLongitudinal studiesOdds ratio Issue Published: 15 July 1992 PDF downloadLoading ...